Matthew C. Foster

Hematology

170 Manning Dr Fl 3
Chapel Hill, NC 27514

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Caregivers' Perspectives on Cancer-Related Cognitive Impairment in Older Adults With Acute Myeloid Leukemia Receiving Chemotherapy.

Caregivers' Perspectives on Cancer-Related Cognitive Impairment in Older Adults With Acute Myeloid Leukemia Receiving Chemotherapy.

Journal: Oncology nursing forum

Published: June 24, 2026

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.

Journal: Cancer research communications

Published: February 17, 2025

Cancer-related cognitive impairment in older adults with acute myeloid leukemia treated with hypomethylating agents and venetoclax chemotherapy: a longitudinal descriptive study.

Cancer-related cognitive impairment in older adults with acute myeloid leukemia treated with hypomethylating agents and venetoclax chemotherapy: a longitudinal descriptive study.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: January 18, 2024

Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms.

Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms.

Journal: Leukemia & lymphoma

Published: November 03, 2023

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.

Journal: Blood advances

Published: April 26, 2023

A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease.

A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease.

Journal: Blood cancer journal

Published: March 29, 2023

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.

Journal: Cancer

Published: October 21, 2022

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.

Journal: Blood advances

Published: July 22, 2022

Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia.

Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia.

Journal: Journal of cellular and molecular medicine

Published: July 08, 2022

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study.

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study.

Journal: Blood advances

Published: April 13, 2022

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.

Journal: Blood advances

Published: January 31, 2022

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens.

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens.

Journal: Haematologica

Published: January 21, 2022

Showing 1-12 of 53

Last Updated: 09/26/2026